000627 Stock Overview
Primarily provides life and motor insurance products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Hubei Biocause Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥4.99 |
| 52 Week High | CN¥5.42 |
| 52 Week Low | CN¥1.61 |
| Beta | 0.68 |
| 1 Month Change | 21.71% |
| 3 Month Change | 60.45% |
| 1 Year Change | 81.45% |
| 3 Year Change | 51.67% |
| 5 Year Change | -29.12% |
| Change since IPO | 906.55% |
Recent News & Updates
Further Upside For Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627) Shares Could Introduce Price Risks After 29% Bounce
Dec 16
Hubei Biocause Pharmaceutical Co., Ltd.'s (SZSE:000627) Shares Leap 43% Yet They're Still Not Telling The Full Story
Oct 23Further Upside For Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627) Shares Could Introduce Price Risks After 32% Bounce
Sep 05Recent updates
Further Upside For Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627) Shares Could Introduce Price Risks After 29% Bounce
Dec 16Hubei Biocause Pharmaceutical Co., Ltd.'s (SZSE:000627) Shares Leap 43% Yet They're Still Not Telling The Full Story
Oct 23Further Upside For Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627) Shares Could Introduce Price Risks After 32% Bounce
Sep 05Improved Revenues Required Before Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627) Shares Find Their Feet
Jun 10Fewer Investors Than Expected Jumping On Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627)
Mar 05Shareholder Returns
| 000627 | CN Insurance | CN Market | |
|---|---|---|---|
| 7D | 3.3% | 0.9% | 0.4% |
| 1Y | 81.5% | 32.7% | 12.3% |
Return vs Industry: 000627 exceeded the CN Insurance industry which returned 32.7% over the past year.
Return vs Market: 000627 exceeded the CN Market which returned 12.3% over the past year.
Price Volatility
| 000627 volatility | |
|---|---|
| 000627 Average Weekly Movement | 13.1% |
| Insurance Industry Average Movement | 4.8% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 13.0% |
| 10% least volatile stocks in CN Market | 5.8% |
Stable Share Price: 000627's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 000627's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 1,765 | Wenxia Zhou | www.biocause.com |
Hubei Biocause Pharmaceutical Co., Ltd. primarily provides life and motor insurance products in China. It also engages in the pharmaceutical, chemical, and new energy fuel businesses. In addition, the company is involved in the contract research and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc.; and provision of chemicals comprising dimethyl ether gas and a-chloropropionyl chloride.
Hubei Biocause Pharmaceutical Co., Ltd. Fundamentals Summary
| 000627 fundamental statistics | |
|---|---|
| Market cap | CN¥23.57b |
| Earnings (TTM) | -CN¥771.87m |
| Revenue (TTM) | CN¥40.70b |
0.6x
P/S Ratio-31.9x
P/E RatioIs 000627 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 000627 income statement (TTM) | |
|---|---|
| Revenue | CN¥40.70b |
| Cost of Revenue | CN¥39.02b |
| Gross Profit | CN¥1.68b |
| Other Expenses | CN¥2.45b |
| Earnings | -CN¥771.87m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.16 |
| Gross Margin | 4.12% |
| Net Profit Margin | -1.90% |
| Debt/Equity Ratio | 48.6% |
How did 000627 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 15:49 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hubei Biocause Pharmaceutical Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jun Liu | Changjiang Securities Co. LTD. |
| Yeyong Meng | SWS Research Co., Ltd. |